Monoclonal antibody · Antagonist of Epidermal growth factor receptor (EGFR)
Phase 2/3Most advanced trial (none active)
1Registered trials
What is Nimotuzumab?
Nimotuzumab is a humanized monoclonal antibody that binds and inhibits the epidermal growth factor receptor (EGFR), resulting in growth inhibition of tumor cells that overexpress EGFR. It is studied in advanced or metastatic pancreatic cancer and may act synergistically with radiation therapy.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
OSAG 101
Drug type
Monoclonal antibody
Targets
Epidermal growth factor receptor (EGFR)
Mechanism
Antagonist of Epidermal growth factor receptor (EGFR)
Pathways
EGFR signaling, growth inhibition of EGFR-overexpressing tumor cells
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.